StockDuty ← Dashboard Aug 14, 2026 07:26 AM ET
SignalCorporate

Karyopharm Q2 Net Loss Expands; Reaffirms 2026 Revenue Guidance; Plans SNDA For Selinexor In August

Reaffirmed 2026 guidance and August SNDA filing signal regulatory catalyst despite wider Q2 loss.

What changed
Reaffirmed 2026 guidance and August SNDA filing signal regulatory catalyst despite wider Q2 loss.
Why it matters
Reaffirmed 2026 guidance and August SNDA filing signal regulatory catalyst despite wider Q2 loss. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →